Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) CEO Sells $229,231.14 in Stock

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) CEO Ted White sold 32,469 shares of Verrica Pharmaceuticals stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $7.06, for a total value of $229,231.14. Following the transaction, the chief executive officer now owns 250,121 shares in the company, valued at approximately $1,765,854.26. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Verrica Pharmaceuticals Trading Up 2.0 %

Shares of Verrica Pharmaceuticals stock opened at $7.25 on Friday. The business’s 50 day simple moving average is $8.03 and its 200 day simple moving average is $6.77. Verrica Pharmaceuticals Inc. has a 52-week low of $2.86 and a 52-week high of $11.41. The company has a debt-to-equity ratio of 29.58, a current ratio of 3.17 and a quick ratio of 3.04.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its earnings results on Monday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.10. Verrica Pharmaceuticals had a negative return on equity of 229.26% and a negative net margin of 905.83%. The business had revenue of $3.83 million for the quarter, compared to analyst estimates of $2.70 million. On average, equities research analysts forecast that Verrica Pharmaceuticals Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

VRCA has been the topic of several recent analyst reports. Needham & Company LLC lifted their price objective on Verrica Pharmaceuticals from $8.00 to $16.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. HC Wainwright lifted their target price on Verrica Pharmaceuticals from $13.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th.

Institutional Investors Weigh In On Verrica Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp increased its position in shares of Verrica Pharmaceuticals by 8.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,680 shares of the company’s stock worth $428,000 after purchasing an additional 4,393 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Verrica Pharmaceuticals by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company’s stock worth $7,511,000 after purchasing an additional 7,609 shares during the last quarter. Perceptive Advisors LLC increased its position in shares of Verrica Pharmaceuticals by 40.9% during the 4th quarter. Perceptive Advisors LLC now owns 7,099,182 shares of the company’s stock worth $51,966,000 after purchasing an additional 2,060,199 shares during the last quarter. Avoro Capital Advisors LLC increased its position in shares of Verrica Pharmaceuticals by 35.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 3,999,999 shares of the company’s stock worth $29,280,000 after purchasing an additional 1,045,935 shares during the last quarter. Finally, BML Capital Management LLC increased its position in shares of Verrica Pharmaceuticals by 20.0% during the 4th quarter. BML Capital Management LLC now owns 180,000 shares of the company’s stock worth $1,318,000 after purchasing an additional 30,000 shares during the last quarter. Institutional investors and hedge funds own 42.45% of the company’s stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.